Oropharyngeal Cancer and the HPV Paradigm Shift
Oropharyngeal carcinoma includes primary tumors of the tonsils, base of tongue, soft palate, and posterior pharyngeal wall. The vast majority are squamous cell carcinomas, and most are now associated with human papillomavirus (HPV). HPV-positive cancers carry a superior prognosis — a fact so significant that the AJCC introduced separate staging systems for HPV-positive and HPV-negative oropharyngeal cancers.
Despite the better outcomes, de-escalation of therapy based solely on HPV status should not be performed outside clinical trials. Trials such as NRG Oncology RTOG 1016 and De-ESCALaTE HPV showed that replacing cisplatin with cetuximab in HPV-positive tumors led to inferior results. Viral testing should be performed in all oropharyngeal carcinoma patients. For a comprehensive overview of target delineation across all anatomical sites, see our complete guide on target volume delineation and field setup.
Anatomy and Patterns of Spread
The oropharynx is a cuboidal space bordered anteriorly by the oral cavity, superiorly by the nasopharynx, and inferiorly by the larynx and hypopharynx. It consists of four subsites: tonsils, base of tongue, soft palate, and pharyngeal wall. In clinical practice, the majority of cases arise in the tonsils and tongue base.
A critical clinical point: the oropharynx has rich lymphatic drainage. Cervical lymph nodes are commonly involved even in early-stage disease. Radiation planning must account for this anatomical reality by ensuring adequate nodal coverage from the outset.
Diagnostic Workup for Target Delineation
Primary site GTV delineation relies on a judicious combination of imaging and physical examination. No single modality does it all — each has a specific role.
Mucosal and superficial disease extent is best assessed by visual inspection, palpation, and fiberoptic endoscopic examination. Photographic documentation at the time of consultation or simulation helps record mucosal extension that may be poorly visualized on imaging — a detail that makes a real difference in contouring.
Contrast-enhanced CT remains the mainstay of diagnostic imaging, but MRI and PET/CT have well-defined roles:
| Modality | Primary Indication | Limitation |
|---|---|---|
| Contrast-enhanced CT | Standard diagnostic imaging; simulation basis | Soft tissue resolution inferior to MRI |
| MRI T1 pre-contrast | Fat plane evaluation and bone marrow signal assessment | Motion artifacts |
| MRI T1 contrast-enhanced | Anterior extension of base of tongue tumors; perineural invasion | May overestimate tumor volume |
| MRI T2 fat-sat | Retropharyngeal nodes; parapharyngeal and pre-epiglottic space extent | Susceptibility artifacts |
| FDG-PET/CT | Complementary metabolic information; detects extent missed by CT/MRI | Poor spatial resolution; low sensitivity for small-volume nodal metastases |
Source: Target Volume Delineation and Field Setup, 2nd Edition (Chapter 2)
An important caveat: absence of FDG uptake in a morphologically suspicious lymph node should not necessarily be considered reassuring. PET has limited sensitivity for small-volume nodal metastases.
Simulation and Daily Localization
The patient is set up supine with head rest and neck extended. Immobilization uses a 5-point Aquaplast thermoplastic mask covering head, neck, and shoulders. A bite-block and/or mouth guard may be inserted. Key instruction: patients must not swallow during scans or treatment.
CT simulation uses IV contrast with ≤3 mm slice thickness, covering from the skull vertex through the carina. The isocenter is typically placed at the arytenoid cartilages. A low anterior conventional AP neck field can be matched to the IMRT fields.
MRI and PET images may be registered or fused to the simulation CT. Using the immobilization mask during PET improves fusion accuracy, but using it during MRI may preclude a dedicated head and neck coil — a practical trade-off the team must weigh case by case.
At Memorial Sloan Kettering Cancer Center (MSKCC), daily image guidance uses linear accelerator-mounted 2D kV imaging and daily cone-beam CT. Alternatives include weekly cone-beam CT with daily kV, ExacTrac (orthogonal kV), or MV CT on TomoTherapy.
IMRT Dose and Fractionation Schemes
Multiple treatment approaches exist. At MSKCC, the preferred technique is sequential, with total gross disease dose of 70 Gy. The specifics differ by HPV status:
HPV-Positive Tumors (Sequential Technique — MSKCC)
Subclinical regions receive 30 Gy in 2 Gy fractions, followed by a cone down delivering 40 Gy in 2 Gy fractions to gross disease. The subclinical region is scrutinized with MRI, contrast CT, and PET/CT to ensure no occult gross disease. If a low anterior AP neck field is matched to IMRT fields, the low neck receives 30 Gy in 2 Gy fractions.
HPV-Negative Tumors (Sequential Technique — MSKCC)
The initial phase delivers 60 Gy in 2 Gy fractions to gross disease while simultaneously treating subclinical regions to 54 Gy in 1.8 Gy fractions. This is followed by a cone down of 10 Gy in 2 Gy fractions to gross disease. The low neck receives 50 Gy in 2 Gy fractions. Reduced elective doses should only be considered when treating with concurrent cisplatin-based chemotherapy.
Simultaneous Integrated Boost (SIB)
Another commonly used technique: gross disease 70 Gy (2 Gy/fx), high-risk subclinical 56 Gy (1.6 Gy/fx), low-risk subclinical 50–52.5 Gy (1.43–1.5 Gy/fx). This technique should only be considered with concurrent chemotherapy. Other fractionation schemes include RTOG 0022 and RTOG 1016.
| Scheme | Gross Disease | High-Risk Subclinical | Low-Risk Subclinical | Note |
|---|---|---|---|---|
| Sequential HPV+ | 70 Gy (30+40 Gy, 2 Gy/fx) | 30 Gy (2 Gy/fx) | 30 Gy low neck | Cone down after 30 Gy |
| Sequential HPV− | 70 Gy (60+10 Gy, 2 Gy/fx) | 54 Gy (1.8 Gy/fx) | 50 Gy low neck | Partial SIB in phase 1 |
| SIB | 70 Gy (2 Gy/fx) | 56 Gy (1.6 Gy/fx) | 50–52.5 Gy (1.43–1.5 Gy/fx) | Requires concurrent chemo |
Source: Target Volume Delineation and Field Setup, 2nd Edition (Chapter 2, Section 2.5.1)
Target Volumes for Gross Disease
The GTV70 encompasses all gross disease as defined by clinical examination and imaging at the primary site, plus all suspicious lymph nodes (>1 cm, necrotic, enhancing, or FDG-avid). Borderline suspicious nodes may receive less than 70 Gy — for example, 60–66 Gy.
| Target Volume | Definition and Description |
|---|---|
| GTV70 | Primary: all gross disease per clinical exam and imaging. Nodes: all suspicious (>1 cm, necrotic, enhancing, FDG-avid). Borderline nodes: 60–66 Gy |
| CTV70 | In areas of excellent visualization: GTV70 = CTV70 (no added margin). With uncertainty: CTV70 = GTV70 + 3–5 mm |
| PTV70 | CTV70 + 3–5 mm depending on daily setup accuracy and image guidance availability |
Source: Target Volume Delineation and Field Setup, 2nd Edition (Table 2.1)
Subclinical Target Volumes
As a general guideline, the primary site CTV should encompass GTV70 + 1 cm, shaved off anatomic barriers to spread (air, bone, skin). From there, each subsite requires specific attention:
Tonsil
Ensure adequate margin (~1 cm) to the primary tumor. With advanced disease, include the pterygoid plates. Consider including the ipsilateral retromolar trigone if anterolateral spread along the pharyngeal constrictor is suspected.
Base of Tongue
The subclinical CTV should cover the glossotonsillar sulcus, vallecula, and pre-epiglottic space. Ensure a mucosal margin of at least 1.0 cm around the base of tongue primary — anteriorly, this may extend into the oral tongue. MRI is very helpful for accurate delineation of anterior tumor extension.
Soft Palate
Cover the entire soft palate, superior aspect of tonsillar pillars and fossa, adjacent nasopharynx superiorly to the pterygoid plate. For advanced primaries, consider the pterygopalatine fossa. If the pterygopalatine fossa is involved, skull base assessment with MRI is required. Ensure adequate anterior coverage — this may require a portion of the hard palate.
Pharyngeal Wall
Generous superior and inferior margins given the possibility of skip lesions. For advanced tumors, consider extending the CTV cranially to include the nasopharynx and caudally to include the hypopharynx.
Elective Neck Nodes
In node-negative cases, at-risk areas include bilateral levels II–IV and lateral retropharyngeal nodes. At MSKCC, levels IB and V are not routinely treated unless grossly involved — the exception being gross oral cavity extension, in which case IB nodes may be at risk.
In node-positive cases, retropharyngeal and retrostyloid nodes should be covered superiorly to the skull base. With gross involvement of low-lying nodes, consider supraclavicular space coverage.
For well-lateralized T1–2, N0–N1 tonsil cancers (≥1 cm from midline), with no base of tongue or soft palate extension: ipsilateral neck treatment is acceptable. The superior extent of node-negative neck coverage may begin at the C1 transverse process or where the posterior belly of the digastric crosses the internal jugular vein.
| Primary Subsite | Subclinical CTV — Key Points |
|---|---|
| Tonsil | GTV + ~1 cm; pterygoid plates in advanced disease; retromolar trigone if anterolateral spread suspected |
| Base of tongue | Glossotonsillar sulcus, vallecula, pre-epiglottic space; mucosal margin ≥1 cm; MRI for anterior extension |
| Soft palate | Entire soft palate, superior tonsillar pillars, adjacent nasopharynx; pterygopalatine fossa if advanced |
| Pharyngeal wall | Generous sup/inf margins (skip lesions); nasopharynx cranially and hypopharynx caudally if advanced |
| Elective nodes (N0) | Bilateral levels II–IV + lateral retropharyngeal; IB only with oral cavity extension |
| Elective nodes (N+) | Retropharyngeal/retrostyloid to skull base; supraclavicular if low nodes involved |
| Lateralized tonsil T1-2 N0-N1 | Ipsilateral neck acceptable; superior coverage from C1 |
Source: Target Volume Delineation and Field Setup, 2nd Edition (Table 2.2)
Practical Considerations and Illustrative Cases
The chapter presents six representative cases illustrating the practical application of these principles:
A patient with HPV-negative cT4N2 squamous cell carcinoma of the left tonsil demonstrates the need for coverage to the pterygoid plates and ipsilateral level IB inclusion due to oral tongue invasion. An HPV-positive cT4N1 base of tongue case illustrates skull base coverage on the node-positive side and bilateral IB consideration when the tumor crosses midline into the oral tongue.
Pre-epiglottic space coverage is demonstrated in base of tongue tumors — an anatomical structure that often harbors subclinical extension and may go unrecognized without dedicated MRI.
A cT1N1 HPV-positive tonsil case with low-lying nodes shows supraclavicular space inclusion. And the cT2N0 HPV-positive well-lateralized tonsil case demonstrates that ipsilateral radiation is viable, with nodal coverage starting at the C1 transverse process and no need to treat level IB. At MSKCC, for tonsil cancers regardless of stage, the ipsilateral subclinical region almost always extends superiorly to include the ipsilateral pterygoid plate.
These examples reinforce that there is no single recipe — each contouring decision balances anatomical tumor extent, nodal status, and HPV to define optimal coverage. Mastery of cervical lymphatic drainage patterns and parapharyngeal spaces is essential for safe and precise planning.
